World-leading pathologist Associate Professor Michael Tetzlaff visits MIA
20 December 2018
Melanoma Institute Australia (MIA) is proud to have one of the world’s leading pathologists, Associate Professor Michael Tetzlaff, with us for this past week.
A/Prof Tetzlaff hails from the Department of Pathology and Translational and Molecular Pathology at the MD Anderson Cancer Centre at The University of Texas.
Spending his time with fellow pathologist Professor Richard Scolyer, MIA’s Co-Medical Director, and his team at Royal Prince Alfred Hospital, A/Prof Tetzlaff is sharing his pathological expertise in primary mucosal melanoma and merkel cell carcinoma, and assisting in the assessment of pathological samples from patients undergoing neoadjuvant, targeted therapy.
Among over 100 published peer-reviewed articles, A/Prof Tetzlaff is also lead author on a paper recently published by the International Neoadjuvant Melanoma Consortium that aims to standardise the pathologic evaluation of resected melanoma metastases following neoadjuvant-targeted or immune-checkpoint therapy.
It is an honour to have Associate Professor Tetzlaff as an international collaborator, and we are delighted to be hosting him on his first ever trip to Australia.
Join in the fun of the virtual event, and together we can run over melanoma!
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.
We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.
A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.
Melanoma March events have been cancelled. A Virtual March will be held on Sunday 29th March. Read this statement from MIA CEO Matthew Browne.
Thank you to the thousands of Aussies who bought ‘Game On Mole‘ t-shirts, took selfies, shared t-shirt pics on social media and started lifesaving conversations around sun safety and skin health.